A human monoclonal antibody against the fibroblast growth factor receptor type 3 (FGFR3), with potential antineoplastic activity. Upon administration, the anti-FGFR3 antibody MFGR1877S binds to and inhibits FGFR3, which may result in the inhibition of both FGFR3 phosphorylation and FGFR3-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death in FGFR3-expressing tumor cells. FGFR3, upregulated or mutated in many tumor cell types, is a receptor tyrosine kinase, and plays a key role in tumor cell proliferation. Check for active clinical trials using this agent.